MDM Group (MDDM)

[ProfitScout]

MDM Group Advises Formal Appointment of Pharmacy Distributor for OraLine in Australia by Harrington Group Limited

SANTA CLARA, CA--(MARKET WIRE)--Apr 28, 2006 -- MDM Group, Inc. (Other OTC:MDDM.PK - News) advises that Harrington Group (Other OTC:HGRLF.PK - News), a division of MDM Group, Gold Ethicals and OTC Limited (Gold) has been appointed as the exclusive Wholesale Distributor of the OraLine drug screening products to the pharmaceutical market in Australia.

Gold is an independent and competitive pharmaceutical wholesaler and distributor headquartered in Melbourne, Australia. Gold was established in 2002 and has expanded rapidly over the past four years. It now represents in excess of 1,400 product lines and has over 1850 active pharmacy accounts.

Substance abuse is a widespread problem in our society. More than six percent of the US population over 12 years of age (13.9 million people) have used drugs within the past thirty days. Rates of use remain highest among persons aged 16 to 25, the age group entering the work force.

Gold will launch the OraLine products across Australia through national pharmacy outlets commencing late May 2006. This retail launch complements Harrington's current promotion of OraLine and other drug screening products to the workplace testing and other markets. OraLine screens simultaneously for any trace of each of the four leading drugs of abuse and will be attractively priced to retail in pharmacies at under $25.

The OraLine saliva drug screen, developed by Harrington's 40% US subsidiary Sun Biomedical Laboratories Inc, has been rated as the best in the market by many independent parties because of its ability to detect the presence of marijuana (THC) at a very low target concentration level (4ng/mL). OraLine is the only available saliva drug screen that meets this low level detection cut-off which is proposed by the US Government as a target standard for workplace screening.

The availability through Australian pharmacies of an affordable, fast, single-step drug screen that can be used in the home or workplace, will provide easy access to parents and employers to the necessary tools that can rapidly detect the recent use of the major drugs of abuse.

This press release is available on the Company's official on-line Investor Relations HUB at http://www.agoracom.com/IR/MDMGroup for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail] where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. Also see www.mdmgroupinc.com.

About MDM Group Inc.

MDM Group develops strategic interests within the Security, Biodefense, Law Enforcement and Homeland Security industries. MDM Group's Biodefense Division is focused on discovery and rapid development of vaccines and other countermeasures to support the Homeland Defense and other stockpile requirements of the United States government and its citizens as well as those in other countries. MDM Group has a controlling interest in Australian listed Harrington Group which is also quoted in the US on the (Other OTC:HGRLF.PK - News).

Safe Harbor Statement

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.


CONTACT INFORMATION

AGORA Investor Relations
http://www.agoracom.com/IR/MDMGroup
Email Contact



---------------------------------------
Source: MDM Group, Inc.